• Mário Lenza, Silvia de Barros Ferraz, Dan Carai Maia Viola, SantosOscar Fernando Pavão dosOF, Miguel Cendoroglo Neto, and Mario Ferretti.
• Hospital Israelita Albert Einstein, São Paulo, SP, Brasil.
• Einstein (Sao Paulo). 2013 Jan 1; 11 (1): 122-7.

ObjectiveTo evaluate effectiveness of the use of platelet-rich plasma as coadjuvant for union of long bones.MethodsThe search strategy included the Cochrane Library (via Central) and MEDLINE (via PubMed). There were no limits as to language or publication media. The latest search strategy was conducted in December 2011. It included randomized clinical trials that evaluated the use of platelet-rich plasma as coadjuvant medication to accelerate union of long bones (acute fractures, pseudoarthrosis and bone defects). The outcomes of interest for this review include bone regeneration, adverse events, costs, pain, and quality of life. The authors selected eligible studies, evaluated the methodological quality, and extracted the data. It was not possible to perform quantitative analysis of the grouped studies (meta-analyses).ResultsTwo randomized prospective clinical trials were included, with a total of 148 participants. One of them compared recombinant human morphogenic bone protein-7 versus platelet-rich plasma for the treatment of pseudoarthrosis; the other evaluated the effects of three coadjuvant treatments for union of valgising tibial osteotomies (platelet-rich plasma, platelet-rich plasma plus bone marrow stromal cells, and no coadjuvant treatment). Both had low statistical power and moderate to high risk of bias.ConclusionThere was no conclusive evidence that sustained the use of platelet-rich plasma as a coadjuvant to aid bone regeneration of fractures, pseudoarthrosis, or bone defects.

9 keywords...

hide…